Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...

In a webinar, panelists discuss Trump's 2025 drug pricing policies, focusing on the Most Favored Nation order, pharmacy ...

The finding that basophil counts may have prognostic significance aligns with a growing body of research into basophils in ...

The Supreme Court decision in Medina v Planned Parenthood interprets the Social Security Acts Medicaid provision as not being ...

Panelists discuss how emerging, better-tolerated oral therapies for idiopathic pulmonary fibrosis (IPF) and progressive ...

Patients with only dry eye had less severe lid margin abnormalities and orifice plugging along with tear film instability ...

Panelists discuss recent trial data demonstrating that a novel agent not only slows lung function decline but also delays ...

Panelists discuss how integrating subcutaneous (SubQ) therapies into oncology practice involves thorough economic evaluation, ...

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

The post hoc analysis of the AGAVE-201 trial found that axatilimab demonstrated consistent response rates in patients with chronic graft-vs-host disease (GVHD), regardless of the number or type of ...

There are significant racial disparities in outpatient referrals for opioid use disorder treatment, highlighting urgent need for targeted interventions in emergency care, according to a recent study.